Recombinant dimeric IgA against EGFR has been shown to be more effective in tumor cell killing than monomeric IgA or IgG1 due to the recruitment of a distinct repertoire of effector functions (Lohse et al., 2011). The gene discussed is CD79A; the disease is neoplasm.